Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced that Ted W. Love, M.D. will join the Board of Directors effective December 1, 2025. Dr. Love brings 30+ years of drug development and global commercialization experience, including leadership roles at Global Blood Therapeutics (CEO until its 2023 acquisition by Pfizer), Onyx, Nuvelo, and Genentech.
The appointment supports Jazz's stated board renewal effort—six directors have been appointed in the past five years—and coincides with the planned retirement of long-tenured director Kenneth O'Keefe, effective December 1, 2025.
Jazz Pharmaceuticals (Nasdaq: JAZZ) annuncia che Ted W. Love, M.D. entrerà nel Board of Directors a partire dal 1 dicembre 2025. Il Dr. Love porta più di 30 anni di esperienza nello sviluppo di farmaci e nella commercializzazione globale, inclusi ruoli di leadership in Global Blood Therapeutics (CEO fino all'acquisizione da parte di Pfizer nel 2023), Onyx, Nuvelo e Genentech.
La nomina sostiene l'obiettivo di rinnovamento del consiglio di Jazz—sei membri sono stati nominati negli ultimi cinque anni—e coincide con il previsto ritiro del direttore di lunga data Kenneth O'Keefe, a partire dal 1 dicembre 2025.
Jazz Pharmaceuticals (Nasdaq: JAZZ) anunció que Ted W. Love, M.D. se unirá al Consejo de Administración a partir del 1 de diciembre de 2025. El Dr. Love aporta más de 30 años de experiencia en desarrollo de fármacos y comercialización global, incluyendo cargos de liderazgo en Global Blood Therapeutics (CEO hasta su adquisición por Pfizer en 2023), Onyx, Nuvelo y Genentech.
El nombramiento apoya el esfuerzo de renovación del consejo de Jazz —se han designado seis directores en los últimos cinco años— y coincide con la prevista retirada del director de larga data Kenneth O'Keefe, a partir del 1 de diciembre de 2025.
Jazz Pharmaceuticals (나스닥: JAZZ)는 Ted W. Love, M.D.가 2025년 12월 1일부로 이사회에 합류한다고 발표했습니다. Love 박사는 글로벌 혈액 치료제(Global Blood Therapeutics)에서의 CEO 재임 기간 포함하여 30년이 넘는 약물 개발 및 글로벌 상업화 경험을 보유하고 있으며, 이에는 Onyx, Nuvelo, Genentech에서의 리더십 역할이 포함됩니다.
이 임명은 Jazz의 명시된 이사회 갱신 노력을 지원하며—지난 5년간 여섯 명의 이사가 선임되었고—또한 장기 재직 이사인 Kenneth O'Keefe의 퇴임 예정과 일치합니다. 퇴임은 2025년 12월 1일에 시행됩니다.
Jazz Pharmaceuticals (Nasdaq : JAZZ) a annoncé que Ted W. Love, M.D. intègrera le conseil d'administration à compter du 1er décembre 2025. Le Dr Love apporte plus de 30 ans d'expérience dans le développement de médicaments et la commercialisation mondiale, notamment des postes de direction chez Global Blood Therapeutics (CEO jusqu'à son rachat par Pfizer en 2023), Onyx, Nuvelo et Genentech.
La nomination soutient l'effort de renouvellement du conseil de Jazz —six administrateurs ont été nommés au cours des cinq dernières années— et coïncide avec le départ prévu du directeur de longue date Kenneth O'Keefe, à compter du 1er décembre 2025.
Jazz Pharmaceuticals (Nasdaq: JAZZ) gab bekannt, dass Ted W. Love, M.D. dem Vorstand ab dem 1. Dezember 2025 beitreten wird. Dr. Love bringt mehr als 30 Jahre Erfahrung in der Arzneimittelentwicklung und globalen Vermarktung mit, darunter Führungspositionen bei Global Blood Therapeutics (CEO bis zur 2023 erfolgten Übernahme durch Pfizer), Onyx, Nuvelo und Genentech.
Die Ernennung unterstützt die angegebene Vorstands-Erneuerungsinitiative von Jazz — sechs Direktoren wurden in den letzten fünf Jahren ernannt — und fällt mit dem geplanten Rücktritt des langjährigen Direktors Kenneth O'Keefe zusammen, der ebenfalls zum 1. Dezember 2025 in Kraft tritt.
Jazz Pharmaceuticals (ناسداك: JAZZ) أعلنت أن تيد دبليو لوف، دكتور في الطب سينضم إلى مجلس الإدارة اعتباراً من 1 ديسمبر 2025. يجلب الدكتور لوف أكثر من 30 عاماً من الخبرة في تطوير الأدوية والتسويق العالمي، بما في ذلك مناصب قيادية في Global Blood Therapeutics (الرئيس التنفيذي حتى استحواذها من قبل Pfizer في 2023)، Onyx، Nuvelo، وGenentech.
ويضفي التعيين دعماً لجهود Jazz المعلنة لتجديد المجلس — تم تعيين ستة أعضاء في السنوات الخمس الماضية — ويتزامن مع تقاعد المدير المخضرم Kenneth O'Keefe، اعتباراً من 1 ديسمبر 2025.
Jazz Pharmaceuticals (纳斯达克股票代码：JAZZ) 宣布，Ted W. Love, M.D. 将于 2025年12月1日 正式加入董事会。Love 博士拥有 超过30年 的药物开发和全球商业化经验，包括在 Global Blood Therapeutics（担任CEO，直到其在 2023 年被辉瑞收购）、Onyx、Nuvelo 和 Genentech 的领导职务。
此任命支持 Jazz 明确的 董事会更新 计划——在过去五年中已任命六名董事——并与长期任职董事 Kenneth O'Keefe 的退休计划相吻合，退休时间为 2025年12月1日。
- Board renewal: 6 directors appointed in past five years
- Dr Love brings 30+ years drug development and commercialization experience
- Led Global Blood Therapeutics to Pfizer acquisition in 2023
- Adds public-board experience at Gilead, Royalty Pharma, Structure Therapeutics
- Departure of Kenneth O'Keefe reduces long-term board continuity since 2004
- Loss of audit committee experience (chaired 2012–2014)
Dr. Love, a biopharmaceutical industry veteran, brings extensive executive leadership and board experience with proven success in creating shareholder value
"We are thrilled to welcome Ted to the Board," said Renee Gala, president and CEO, Jazz Pharmaceuticals. "His proven success in the biopharmaceutical industry and track record driving scientific innovation, commercial success and shareholder value will complement the capabilities of our existing Board as we deliver on our future growth strategy and deepen our commitment to innovating for patients."
Dr. Love was the President and Chief Executive Officer of Global Blood Therapeutics, Inc. from 2014 until its acquisition by Pfizer in 2023, where he led the company from a startup into a global commercial business with a pipeline of innovative therapies. Previous leadership experience also has included Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc. and President and Chief Executive Officer/Chairman of Nuvelo, Inc. He started his biotech career at Genentech, Inc, holding several management positions. Dr. Love received a B.A. degree in molecular biology from Haverford College and his medical degree from Yale Medical School. He completed a residency in internal medicine and a fellowship in cardiology at the Massachusetts General Hospital.
Dr. Love currently serves on the board of directors of Gilead Sciences, Royalty Pharma plc, and Structure Therapeutics Inc. As the Immediate Past Chair of the BIO Board of Directors, Dr. Love also brings deep expertise on biopharmaceutical public policy matters surrounding scientific innovation and patient access.
"I am impressed by the strength of Jazz's current business and future potential to support more patients with unmet medical needs," said Dr. Love. "I am excited to be joining Jazz at this pivotal moment for the Company, and to work with my colleagues on the Board and the management team to deliver on the Company's growth strategy and create sustained value for our shareholders, patients and employees."
Dr. Love's appointment reflects Jazz's ongoing focus on Board renewal with six of the Company's directors appointed in the past five years.
Additionally, Kenneth O'Keefe has informed the Company of his intention to retire from the Jazz Board, effective December 1, 2025.
"In addition to welcoming Ted to our Board, I want to thank Ken for his service to Jazz and his incredible leadership over the years," said Bruce Cozadd, chairperson, Jazz Pharmaceuticals. "Ken has been a valued member of the Jazz Board during our journey from a small single product organization to a global biopharma company, contributing deep and thoughtful business and financial expertise as we grew and diversified our business. We have been grateful for his dedication and partnership and wish him well as he transitions off the Board."
Mr. O'Keefe has served on the Jazz board since 2004, including as a valued member of the audit committee (which he chaired from 2012 to 2014). Mr. O'Keefe served as Managing Director and Chief Executive Officer of BPOC, LLC, a healthcare private equity firm he co-founded. He serves on the boards of several privately-held healthcare companies.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.
Contacts:
Jazz Media Contact:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
Jazz Investor Contact:
Jack Spinks
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
investorinfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-appoints-ted-w-love-md-to-its-board-of-directors-302597353.html
SOURCE Jazz Pharmaceuticals plc
FAQ
When does Ted W. Love join the Jazz Pharmaceuticals board (JAZZ)?
What experience does Ted W. Love bring to Jazz (JAZZ)?
How does Ted Love's appointment affect Jazz's board composition (JAZZ)?
Who is retiring from the Jazz board and when will the retirement be effective (JAZZ)?
Did Ted Love have a role in a major acquisition prior to joining Jazz (JAZZ)?
Will Ted Love bring public-company board experience relevant to Jazz (JAZZ)?
